In December 2019, an outbreak of pandemic severe respiratory distress syndrome
coronavirus disease 2019 (COVID-19) initially occurred in China, has spread the world …

Immunosuppression and immunomodulation are valuable therapeutic approaches for
managing neuroimmunological diseases. In times of the Coronavirus disease 2019 (COVID …

The importance of reported neurological manifestations of coronavirus disease 2019
(COVID-19) is still unclear. Nevertheless, an immediate and ongoing neurological challenge …

It is just over eighteen months since the recognition of the novel coronavirus 2019 (COVID-
19); as many areas of the world begin to take steps towards safely returning to normal …

Abstract The coronavirus disease 2019 (COVID-19) pandemic is concerning for patients with
neuroimmunological diseases who are receiving immunotherapy. Uncertainty remains …

Although SARS-CoV-2 causes a respiratory viral infection, there is a large incidence of
neurological complications occurring in COVID-19 patients. These range from headaches …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the aetiologic agent of the
coronavirus disease 2019 (COVID-19), is now rapidly disseminating throughout the world …

Introduction Among the clinical manifestations of SARS-CoV-2 infection, neurological
features have been commonly reported and the state-of-the-art technique suggests several …

With interest we read the article by Kayhanian et al. about the presumed neuro-
immunological mechanisms underlying the involvement of the central nervous system (CNS) …

Abstract Coronavirus disease 2019 (COVID-19) is an infectious respiratory disease, caused
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidence-based …